Browse > Article
http://dx.doi.org/10.5352/JLS.2010.20.12.1792

Structure Determination of Macrolactin Compounds with Antibacterial Activities Isolated from Bacillus polyfermenticus KJS-2  

Kim, Dong-Hee (Research and Development Center, Daewoo Pharmaceutical Co,. Ltd.)
Kang, Kyung-Ran (Research and Development Center, Daewoo Pharmaceutical Co,. Ltd.)
Kim, Hyun-Woo (Technical Research Institute, Daesun Distilling Co., Ltd.)
Yoon, Si-Yeol (Department of Pharmaceutical Engineering, Inje University)
Kim, Chun-Gyu (Department of Pharmaceutical Engineering, Inje University)
Yamaguchi, Tokutaro (Department of Pharmaceutical Engineering, Sun Moon University)
Sohng, Jae-Kyung (Department of Pharmaceutical Engineering, Sun Moon University)
Kang, Jae-Seon (Department of Pharmacy, Kyungsung University)
Publication Information
Journal of Life Science / v.20, no.12, 2010 , pp. 1792-1800 More about this Journal
Abstract
In this study, we isolated five macrolactin compounds from a fermentation broth of Bacillus polyfermenticus KJS-2. The macrolactin compounds were structurally identified as macrolactin A (MA), 7-O-malonyl macrolactin A (MMA), 7-O-succinyl macrolactin A (SMA), macrolactin E (ME) and macrolactin F (MF) via a variety of NMR techniques, COZY, DEPT, HMQC and HMBC, and mass and specific rotation assays. The three macrolactin compounds, MA, MMA and SMA, profoundly inhibited the growth of both vancomycin-resistant Enterococci (VREs) and methicillin-resistant Staphylococcus aureus (MRSA), the inhibition of which were estimated via a disc agar diffusion bioassay. MA, MMA, and SMA exhibited antibacterial activities superior to those of vancomycin and teicoplanin.
Keywords
Bacillus polyfermenticus KJS-2; macrolactin; antibacterial activity; vancomycin-resistant Enterococcus; methicillin-resistant Staphylococcus aureus;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Arthur, M. and R. Quintiliani. 2001. Regulation of VanA‑and VanB‑type glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 45, 375-381.   DOI
2 Auckland, C., L. Teare, F. Cooke, M. E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A. P. Johnson. 2002. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50, 743-746.   DOI
3 Bagga, B. and J. L. Shenep. 2010. Management of infections caused by vancomycin-resistant Gram-positive bacteria. Pediatr. Infect. Dis. J. 29, 662-664.   DOI
4 Choi, S. W., D. H. Bai, J. H. Yu, and C. S. Shin. 2003. Characteristics of the squalene synthase inhibitors produced by a Streptomyces species isolated from soils. Can. J. Microbiol. 49, 663-668.   DOI
5 Cosgrove, S. E., G. Sakoulas, E. N. Perencevich, M. J. Schwaber, A. W. Karchmer, and Y. Carmeli. 2003. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis. 36, 53-59.   DOI
6 Fraser, T. G., C. Hansen, and J. K. Long. 2006. Newer antibiotics for serious gram-positive infections. Cle. Clin. J. Med. 73, 847-853.   DOI
7 Goll, C., P. Balmer, F. Schwab, H. Rüden, and T. Eckmanns. 2007. Different trends of MRSA and VRE in a German Hospital, 1999-2005. Infection 35, 245-249.   DOI
8 Gustafson, K., M. Roman, and W. Fenical. 1989. The macrolactins, a novel class of antiviral and cytotoxic macrolides from a deep-sea marine bacterium. J. Am. Chem. Soc. 111, 7519-7524.   DOI
9 Yoo, J. S., C. J. Zheng, S. K. Lee, J. H. Kwak, and W. G. Kim. 2006. Macrolactin N, a new peptide deformylase inhibitor produced by Bacillus subtilis. Bioorg. Med. Chem. Lett. 16, 4889-4892.   DOI
10 Zheng, C. J., S. K. Lee, C. H. Lee, and W. G. Kim. 2007. Macrolactins O-R, glycosylated 24-membered lactones from Bacillus sp. AH159-1. J. Nat. Prod. 70, 1632-1635.   DOI
11 Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40, 839-845.
12 Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, and R. C. Moellering. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208.   DOI
13 Norrby, S. R. 1995. Emerging antibiotic resistance in Gram positive bacteria: return to the pre-antibiotic era? HKMJ. 1, 129-135.
14 Presterl, E., W. Graninger, and A. Georgopoulos. 1993. The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria. J. Antimicrob. Chemother. 31, 755-766.   DOI
15 Rice, L. B. 2006. Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control. 34, S11-S19.   DOI
16 Romero-Tabarez, M., R. Jansen, M. Sylla, H. Lunsdorf, S. Haubler, D. A. Santosa, K. N. Timmis, and G. Molinari. 2006. 7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and a small-colony variant of Burkholderia cepacia. Antimicrob. Agents Chemother. 50, 1701-1709.   DOI
17 Sohn, M. J., C. J. Zheng, and W. G. Kim. 2008. Macrolactin S, a new antibacterial agent with Fab G-inhibitory activity from Bacillus sp. AT28. J. Antibiot. 61, 687-691.   DOI
18 Van der Auwera, P., M. Aoun, and F. Meunier. 1991. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob. Agents Chemother. 35, 451-457.   DOI   ScienceOn
19 Von Baum, H., J. F. Ober, C. Wendt, R. P. Wenzel, and M. B. Edmond. 2005. Antibiotic-resistant bloodstream infections in hospitalized patients: specific risk factors in a high-risk population? Infection. 33, 320-326.   DOI
20 Xue, C., L. Tian, M. Xu, Z. Deng, and W. Lin. 2008. A new 24-membered lactone and a new polyene $\delta$-lactone from the marine bacterium Bacillus Marinus. J. Antibiot. 61, 668-674.   DOI
21 Han, J. S., J. H. Cheng, T. M. Yoon, J. Song, A. Rajkarnikar, W. G. Kim, I. D. Yoo, and Y. Y. Yang. 2005. Biological control agent of common scab disease by antagonistic strain Bacillus sp. sunhua. J. Appl. Microbiol. 99, 213-221.   DOI
22 Jaruchoktaweechai, C., K. Suwanborirux, S. Tanasupawatt, P. Kittakoop, and P. Menasveta. 2000. New macrolactins from a marine Bacillus sp. Sc026. J. Nat. Prod. 63, 984-986.   DOI
23 Lee, S. J., J. Y. Cho, J. H. Moon, K. D. Park, Y. J. Lee, and K. H. Park. 2004. Isolation and characterization of antimicrobial substance macrolactin A produced from Bacillus amyloliquefaciens CHO104 isolated from soil. J. Microbiol. Biotechnol. 14, 525-531.   과학기술학회마을
24 Kim, H. H., W. G. Kim, I. J. Ryoo, C. J. Kim, J. E. Suk, K. H. Han, S. Y. Hwang, and I. D. Yoo. 1997. Neuronal cell protection activity of macrolactin A produced by Actinomadura sp. J. Microbiol. Biotechnol. 7, 429-434.   과학기술학회마을
25 Kim, K. M., M. J. Kim, D. H. Kim, Y. S. Park, and J. S. Kang. 2009. Characterization of Bacillus polyfermenticus KJS-2 as a Probiotic. J. Microbiol. Biotechnol. 19, 1013-1018.   과학기술학회마을   DOI
26 Lee, K. H., K. D. Jun, W. S. Kim, and H. D. Paik. 2001. Partial characterization of polyfermenticin SCD, a newly identified bacteriocin of Bacillus polyfermenticus. Lett. Appl. Microbiol. 32, 146-151.   DOI
27 Lentino, J. R., M. Narita, and V. L. Yu. 2008. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. 27, 3-15.   DOI
28 Nagao, T., M. Adachi, M. Sakai, M. Nishijima, and H. Sano. 2001. Novel macrolactins as antibiotic lactones from a marine bacterium. J. Antibiot. 54, 333-339.   DOI   ScienceOn
29 Neu, H. C. 1992. The crisis in antibiotic resistance. Science 254, 1064-1073.